|Bid||52.62 x 3100|
|Ask||52.70 x 1800|
|Day's range||51.44 - 52.77|
|52-week range||36.15 - 64.94|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||55.38|
|Forward dividend & yield||1.40 (2.66%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||60.63|
They could add up to make Moderna a much bigger winner for investors than either of the two big pharma stocks.
In the last three weeks, the world has let out a collective sigh of relief on positive news from coronavirus vaccine trials reported by Pfizer (NYSE: PFE) and partner BioNTech (NASDAQ: BNTX), Moderna (NASDAQ: MRNA), and AstraZeneca (NASDAQ: AZN). Despite the market's reaction, I think investors have more to be excited about from the potential AstraZeneca vaccine than its efficacy data suggests. AstraZeneca and the University of Oxford's recent announcement that their vaccine candidate had 70% overall effectiveness at preventing COVID-19 requires a little more digging.
This is on top of the 5 million doses it already put its name down for two weeks ago, and is subject to approval from the Medicines and Healthcare products Regulatory Agency (MHRA).